Cargando…
Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy
Although the majority of smooth muscle neoplasms found in the uterus are benign, uterine leiomyosarcoma (LMS) is extremely malignant, with high rates of recurrence and metastasis. We earlier reported that mice with a homozygous deficiency for LMP2, an interferon (IFN)-γ-inducible factor, spontaneous...
Autores principales: | Hayashi, Takuma, Horiuchi, Akiko, Sano, Kenji, Hiraoka, Nobuyoshi, Kasai, Mari, Ichimura, Tomoyuki, Sudo, Tamotsu, Tagawa, Yoh-ichi, Nishimura, Ryuichiro, Ishiko, Osamu, Kanai, Yae, Yaegashi, Nobuo, Aburatani, Hiroyuki, Shiozawa, Tanri, Konishi, Ikuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3240965/ https://www.ncbi.nlm.nih.gov/pubmed/22355695 http://dx.doi.org/10.1038/srep00180 |
Ejemplares similares
-
Involvement of proteasome β1i subunit, LMP2, on development of uterin leiomyosarcma
por: Hayashi, Takuma, et al.
Publicado: (2011) -
Molecular Approach to Uterine Leiomyosarcoma: LMP2-Deficient Mice
as an Animal Model of Spontaneous Uterine Leiomyosarcoma
por: Hayashi, Takuma, et al.
Publicado: (2011) -
Potential Biomarker for Human Uterine Leiomyosarcoma
por: Hayashi, Takuma, et al.
Publicado: (2014) -
Molecular Mechanisms of Uterine Leiomyosarcomas: Involvement of Defect in LMP2 Expression
por: Hayashi, Takuma, et al.
Publicado: (2008) -
Profiling of Target Molecules for Immunotherapy in Mesenchymal Tumors
por: Hayashi, Takuma, et al.
Publicado: (2019)